Mirai Bio Appoints New President and COO

Mirai Bio has announced the appointment of Jens Vogel, Ph.D., as President and Chief Operating Officer. With extensive experience in biopharmaceutical development, including his roles at Bayer and Boehringer Ingelheim, Dr. Vogel will play a pivotal role in expanding Mirai's platform for the development of genetic medicines. His leadership aims to accelerate Mirai's mission of advancing nucleic acid-based therapies through a machine intelligence-driven platform that designs and optimizes delivery vehicles for various tissues and cells.

Dr. Vogel’s expertise, especially in cell and gene therapies, will further strengthen Mirai's capacity to address critical challenges in in vivo delivery systems. The company’s platform has already made significant strides in enhancing the design, delivery, and manufacturing processes for genetic medicines, making it an important player in the biotech field. His appointment signals the next phase of Mirai's growth, driving deeper collaborations and broadening the impact of its technology.

Dr. Hari Pujar, Mirai's co-founder, expressed confidence that Vogel’s leadership will help unlock new value for patients and partners. Mirai's ability to integrate innovations across various aspects of genetic medicine development is set to transform therapeutic options for a wide range of diseases, accelerating progress towards clinical success.